Sign in

    Gregory J. Divis

    Chief Executive Officer and Director at Avadel Pharmaceuticals PLC
    Board
    Since June 2019
    Age
    58 years
    Education
    Earned a B.S. (Bachelor of Science) degree from the University of Iowa.
    Tenure
    Joined Avadel Pharmaceuticals in January 2017 as Executive Vice President and Chief Commercial Officer, was promoted to Chief Operating Officer in March 2018, served as Interim CEO in January 2019, and was appointed as Chief Executive Officer and Director in June 2019.

    Also at Avadel Pharmaceuticals PLC

    JGS
    Jerad G. Seurer
    General Counsel and Corporate Secretary
    RJK
    Richard J. Kim
    Chief Commercial Officer
    TSM
    Thomas S. McHugh
    Chief Financial Officer

    About

    Gregory J. Divis, born in 1967 and 58 years old as of March 2025 , has developed a robust career in the pharmaceutical industry over the past 25 years. He is a graduate of the University of Iowa, where he earned his B.S. degree, laying the foundation for his professional journey.

    Before joining Avadel Pharmaceuticals, Divis held several prominent roles in the industry. He served as President and Chief Executive Officer of Lumara Health (formerly K-V Pharmaceutical Company), contributed as President of Ther-Rx Corporation, and held significant roles at Sanofi-Aventis and Schering-Plough Corporation. His early career also included a stint as an Executive-in-Residence at Linden Capital Partners, demonstrating his versatility and depth in healthcare business operations.

    At Avadel Pharmaceuticals, his trajectory has been marked by rapid progression. He joined the company in January 2017 as Executive Vice President and Chief Commercial Officer, was elevated to Chief Operating Officer in March 2018, and then served as Interim CEO in January 2019 before taking on the current position as Chief Executive Officer and Director in June 2019.

    Under his leadership, the company has benefited from his extensive expertise in strategic operations and commercial strategy, driving growth and positioning Avadel strongly within the competitive pharmaceutical sector.

    $AVDL Performance Under Gregory J. Divis

    Past Roles

    Organization Role Date Range Details
    Avadel Pharmaceuticals (AVDL) Executive Vice President and Chief Commercial Officer January 2017 – March 2018 Managed commercial strategy and execution; ended with promotion
    Avadel Pharmaceuticals (AVDL) Chief Operating Officer March 2018 – January 2019 Oversaw commercial strategy and operations; transitioned to interim CEO
    Avadel Pharmaceuticals (AVDL) Interim Chief Executive Officer January 2019 – May 2019 Served as interim CEO prior to his permanent appointment as CEO
    Linden Capital Partners Operating Partner / Executive-in-Residence June 2015 – December 2016 Middle-market healthcare-focused private equity firm role
    K-V Pharmaceutical Company / Lumara Health President and Chief Executive Officer May 2010 – November 2014 Led the company through Chapter 11 bankruptcy filing on August 4, 2012, emergence on September 16, 2013, and acquisition by AMAG Pharmaceuticals in November 2014
    Ther-Rx Corporation President N/A Subsidiary of K-V Pharmaceutical Company
    Sanofi-Aventis Vice-President, Business Development & Lifecycle Management N/A N/A
    Schering-Plough Corporation Vice-President and General Manager, UK and Ireland N/A N/A

    External Roles

    Organization Role Date Range Details
    Jaguar Health, Inc. Board of Directors Current Publicly traded pharmaceutical company

    Fixed Compensation

    Data from  FY 2023
    Component NameAmountPayment ScheduleAdditional Details
    Base Salary$600,000 AnnualFixed annual base salary
    All Other Compensation$25,200 AnnualIncludes Employer 401(k) Contributions: $13,200 and Auto Allowance: $12,000

    Performance Compensation

    Data from  FY 2023

    Annual Cash Incentive Award for 2023

    MetricValueDetails
    Performance MetricsCorporate performance goals Includes achieving LUMRYZ launch revenue and patient demand targets, meeting operating expense and cash balance targets
    Target Bonus$360,000 60% of the base salary ($600,000)
    Actual Awarded$360,000 Fully awarded based on a 100% corporate performance score
    Vesting ScheduleN/ANo vesting; bonus is paid out annually based on performance
    Evaluation PeriodCalendar Year 2023 Performance evaluated over the full year 2023

    Equity Awards (Performance Share Units) for 2023

    MetricValueDetails
    PSU Target175,000 PSUs Target number of performance share units awarded
    Performance MetricsCorporate objectives Based on achieving corporate objectives including exceeding revenue and patient demand forecasts
    Vesting ScheduleOne-third H2 2023; Two-thirds Calendar Year 2024 Vesting is split between performance in the second half of 2023 and the entirety of calendar year 2024
    Grant Date / Fair Value / Stock PriceN/ANot applicable as grant date not set for accounting purposes due to discretionary performance criteria
    Threshold/Target/WeightsN/ASpecific thresholds or weightings were not disclosed